Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.
Also called NCT01135992
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 143 participants
- Sponsor
- Registry
-
NCT01135992
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01135992. Non-randomized; no masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2010-11 (actual). Results posted on 2016-01-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
- Acronym
- BEGIN™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01135992- Content hash
6d9600a1bfd13b8c654b4fcb86ba958b1f9542e5129458b9abff062c7e0c34a3